8-K: SCYNEXIS & GSK Resolve Dispute, Secure $24.3M Payment

SCYNEXIS and GSK have resolved their disagreement regarding the MARIO study, leading to a $24.3 million payment to SCYNEXIS and continued collaboration on BREXAFEMME.

Summary

• SCYNEXIS, Inc. and GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) entered into a binding memorandum of understanding (Binding 2025 MOU) on October 14, 2025, to amend their exclusive license agreement.
• The Binding 2025 MOU resolves a previously disclosed disagreement between the parties concerning the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis.
• SCYNEXIS has agreed to promptly wind-down and terminate the MARIO Study.
• SCYNEXIS will receive a $22 million payment from GSK as part of the resolution.
• An additional $2.3 million payment will be received from GSK in connection with the wind-down and termination activities of the MARIO Study.
• SCYNEXIS will not receive any additional milestone payments specifically associated with the MARIO Study.
• GSK has reiterated its commitment to continued collaboration regarding other aspects of the Exclusive License Agreement, including the commercialization of BREXAFEMME (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) and refractory VVC (rVVC) indications.
• SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025.
• GSK anticipates initiating regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC in the U.S. market.
• Except for the MARIO Study, the Binding 2025 MOU does not alter the potential milestones and royalties payable to SCYNEXIS under the Exclusive License Agreement, including for sales of BREXAFEMME for VVC and rVVC.

Sentiment

Score: 7

Explanation: The resolution of a significant disagreement and the receipt of $24.3 million in cash are strong positives, providing financial stability and clarity. While the termination of the MARIO study is a negative for that specific indication, the continued commitment from GSK for BREXAFEMME's approved uses balances the overall sentiment towards positive.

Positives

• Resolution of a significant disagreement with GSK, removing uncertainty regarding the MARIO study.
• Receipt of a total of $24.3 million in payments from GSK ($22 million for resolution and $2.3 million for wind-down activities), providing immediate cash inflow.
• GSK has reiterated its commitment to the continued collaboration and commercialization of BREXAFEMME for VVC and rVVC, ensuring ongoing partnership for approved indications.
• Potential for future milestones and royalties from BREXAFEMME sales for VVC and rVVC remains unchanged.
• Clear timeline for the transfer of the BREXAFEMME NDA to GSK by the end of 2025.
• Anticipated initiation of regulatory interactions by GSK with the FDA in 2026 for BREXAFEMME's U.S. relaunch for VVC and rVVC.

Negatives

• Termination of the Phase 3 MARIO study for invasive candidiasis, halting development for this specific indication.
• Loss of potential future milestone payments specifically associated with the MARIO Study.

Risks

• The Binding 2025 MOU is a summary, and the full agreement, which SCYNEXIS intends to file with its Annual Report on Form 10-K, may contain additional details or terms.
• Confidential treatment will be requested for certain portions of the Binding 2025 MOU, limiting public transparency on specific terms.
• The anticipated regulatory interactions by GSK with the FDA in 2026 for BREXAFEMME's relaunch are subject to regulatory approval and may not proceed as expected or on the anticipated timeline.
• The commercial success of BREXAFEMME for VVC and rVVC in the U.S. market depends on GSK's marketing and sales efforts, as well as market acceptance.

Future Outlook

GSK anticipates initiating regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market. SCYNEXIS expects to complete the transfer of the BREXAFEMME NDA to GSK by the end of 2025.

Management Comments

• GSK has reiterated its commitment to continued collaboration with SCYNEXIS regarding other aspects of the Exclusive License Agreement, including with respect to the commercialization of BREXAFEMME for the VVC and rVVC indications.

Industry Context

This filing highlights the inherent risks and complexities in pharmaceutical drug development, particularly in late-stage clinical trials. The termination of a Phase 3 study, even with a financial settlement, underscores the high attrition rate for drug candidates. However, the continued commitment from a major pharmaceutical partner like GSK for the commercialization of an approved product (BREXAFEMME for VVC/rVVC) provides a degree of stability and validation for SCYNEXIS's core asset in its approved indications, contrasting with the challenges faced in new indications.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to immediate cash inflow ($24.3 million) and resolution of a dispute, reducing uncertainty. Continued potential for royalties from BREXAFEMME sales. Negative impact from the termination of a Phase 3 study for a new indication.
• Employees: Potential impact on employees involved in the MARIO study wind-down, though not explicitly stated.
• Patients/Healthcare Providers: The MARIO study termination means ibrexafungerp will not be pursued for invasive candidiasis by GSK, potentially limiting future treatment options for that specific condition. However, BREXAFEMME remains available and will be relaunched for VVC/rVVC.

Next Steps

• SCYNEXIS to promptly wind-down and terminate the MARIO Study.
• SCYNEXIS to transfer the BREXAFEMME NDA to GSK by the end of 2025.
• GSK to initiate regulatory interactions with the U.S. FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC.
• SCYNEXIS intends to file the Binding 2025 MOU with its Annual Report on Form 10-K for the year ending December 31, 2025.

Key Dates

Recommendation

The immediate cash infusion of $24.3 million and the resolution of a material disagreement with GSK provide short-term financial stability and remove a significant overhang. This is a clear positive. However, the termination of the Phase 3 MARIO study for invasive candidiasis represents a narrowing of the development pipeline for ibrexafungerp, limiting its future market potential beyond VVC/rVVC. While GSK's commitment to relaunch BREXAFEMME for VVC/rVVC is encouraging, the success and timing of this relaunch remain future events. Given these balancing factors, a 'hold' recommendation is appropriate, awaiting further clarity on BREXAFEMME's commercial performance post-relaunch and SCYNEXIS's broader pipeline strategy.

Keywords

SCYNEXIS, GSK, ibrexafungerp, BREXAFEMME, MARIO study, invasive candidiasis, vulvovaginal candidiasis, rVVC, license agreement, pharmaceutical, biotech, FDA, NDA, milestone payments, royalties